Загрузка...
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
Glycemic control has been considered a major therapeutic goal within the scope of diabetes management, as supported by robust observational and experimental evidence. However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the...
Сохранить в:
| Опубликовано в: : | Diabetol Metab Syndr |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5883417/ https://ncbi.nlm.nih.gov/pubmed/29636825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-018-0327-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|